These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24132773)

  • 1. Pharmacodynamics and pharmacokinetics of a novel, low-dose, soft-gel capsule of acetylsalicylic acid in comparison with an oral solution after single-dose administration to healthy volunteers: a phase I, two-way crossover study.
    Loprete L; Leuratti C; Scarsi C; Radicioni M
    Clin Drug Investig; 2014 Jan; 34(1):19-25. PubMed ID: 24132773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation.
    Patrick J; Dillaha L; Armas D; Sessa WC
    Postgrad Med; 2015 Aug; 127(6):573-80. PubMed ID: 25998572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining platelet response to acetylsalicylic acid: the relation between inhibition of serum thromboxane B
    Gurbel PA; Bliden KP; Tantry US
    J Thromb Thrombolysis; 2021 Feb; 51(2):260-264. PubMed ID: 33170486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study.
    Franchi F; Schneider DJ; Prats J; Fan W; Rollini F; Been L; Taatjes-Sommer HS; Bhatt DL; Deliargyris EN; Angiolillo DJ
    J Thromb Thrombolysis; 2022 Oct; 54(3):373-381. PubMed ID: 36036856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole.
    Offman E; Schobelock MJ; Brickl R; VanderMaelen CP; Ehrlich J; Eisert W
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):113-20. PubMed ID: 23532686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers.
    Andersson T; Morrison D; Nagy P; Pisupati J; Schettler J; Warner TD
    Am J Cardiovasc Drugs; 2012 Aug; 12(4):217-24. PubMed ID: 22631032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus.
    Bhatt DL; Grosser T; Dong JF; Logan D; Jeske W; Angiolillo DJ; Frelinger AL; Lei L; Liang J; Moore JE; Cryer B; Marathi U
    J Am Coll Cardiol; 2017 Feb; 69(6):603-612. PubMed ID: 28089180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study.
    Angiolillo DJ; Bhatt DL; Lanza F; Cryer B; Dong JF; Jeske W; Zimmerman RR; von Chong E; Prats J; Deliargyris EN; Marathi U
    J Thromb Thrombolysis; 2019 Nov; 48(4):554-562. PubMed ID: 31420787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects.
    Bode-Böger SM; Böger RH; Schubert M; Frölich JC
    Eur J Clin Pharmacol; 1998; 54(9-10):707-14. PubMed ID: 9923572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers.
    Cox D; Maree AO; Dooley M; Conroy R; Byrne MF; Fitzgerald DJ
    Stroke; 2006 Aug; 37(8):2153-8. PubMed ID: 16794200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers.
    Benedek IH; Joshi AS; Pieniaszek HJ; King SY; Kornhauser DM
    J Clin Pharmacol; 1995 Dec; 35(12):1181-6. PubMed ID: 8750369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetylsalicylic acid in critically ill patients: a cross-sectional and a randomized trial.
    Schoergenhofer C; Hobl EL; Schwameis M; Gelbenegger G; Staudinger T; Heinz G; Speidl WS; Zauner C; Reiter B; Lang I; Jilma B
    Eur J Clin Invest; 2017 Jul; 47(7):504-512. PubMed ID: 28556061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics and safety of a fixed-dose combination of acetylsalicylic acid and clopidogrel compared with the concurrent administration of acetylsalicylic acid and clopidogrel in healthy subjects: a randomized, open-label, 2-sequence, 2-period, single-dose crossover study.
    Jung JA; Kim TE; Kim JR; Kim MJ; Huh W; Park KM; Lee SY; Ko JW
    Clin Ther; 2013 Jul; 35(7):985-94. PubMed ID: 23870608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
    Patel A; Shah T; Shah G; Jha V; Ghosh C; Desai J; Khamar B; Chakraborty BS
    Am J Cardiovasc Drugs; 2010; 10(2):95-103. PubMed ID: 20334446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes.
    Cerletti C; Dell'Elba G; Manarini S; Pecce R; Di Castelnuovo A; Scorpiglione N; Feliziani V; de Gaetano G
    Clin Pharmacokinet; 2003; 42(12):1059-70. PubMed ID: 12959636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of two preparations of 75-mg extended-release aspirin on platelet aggregation, prostanoids and nitric oxide production in humans.
    de la Cruz JP; Guerrero A; González-Correa JA; Márquez E; Nacle I; Sánchez de la Cuesta F
    Eur J Clin Pharmacol; 2002 Jan; 57(11):775-80. PubMed ID: 11871383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation.
    Petrides PE; Gisslinger H; Steurer M; Linkesch W; Krumpl G; Schüller A; Widmann R
    Clin Ther; 2009 Feb; 31(2):386-98. PubMed ID: 19302911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution.
    Feldman M; Cryer B
    Am J Cardiol; 1999 Aug; 84(4):404-9. PubMed ID: 10468077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
    Kim SD; Kang W; Lee HW; Park DJ; Ahn JH; Kim MJ; Kim EY; Kim SW; Nam HS; Na HJ; Yoon YR
    Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.